Amalgamated Bank Reduces Stake in Catalent, Inc. (NYSE:CTLT)

Amalgamated Bank reduced its position in Catalent, Inc. (NYSE:CTLT) by 32.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 36,840 shares of the company’s stock after selling 17,639 shares during the period. Amalgamated Bank’s holdings in Catalent were worth $2,072,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of CTLT. Lindbrook Capital LLC boosted its stake in shares of Catalent by 79.4% in the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after buying an additional 208 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Catalent in the 2nd quarter worth $42,000. Mather Group LLC. purchased a new position in shares of Catalent in the 1st quarter worth $52,000. Longfellow Investment Management Co. LLC boosted its stake in shares of Catalent by 45.7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after buying an additional 305 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after purchasing an additional 212 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. StockNews.com assumed coverage on shares of Catalent in a research report on Wednesday, September 18th. They issued a “sell” rating for the company. Robert W. Baird restated a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday. Barclays upped their target price on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a report on Friday, June 28th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 price target on shares of Catalent in a report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating and seven have issued a hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $59.83.

Catalent Trading Up 0.7 %

Shares of Catalent stock opened at $60.14 on Wednesday. Catalent, Inc. has a twelve month low of $31.80 and a twelve month high of $61.20. The company has a quick ratio of 1.77, a current ratio of 2.52 and a debt-to-equity ratio of 1.35. The business has a 50-day moving average price of $59.56 and a 200-day moving average price of $57.27. The firm has a market cap of $10.88 billion, a price-to-earnings ratio of -9.86, a PEG ratio of 1.88 and a beta of 1.15.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Thursday, August 29th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.13. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The business had revenue of $1.30 billion during the quarter, compared to analysts’ expectations of $1.23 billion. Equities research analysts anticipate that Catalent, Inc. will post 1.06 EPS for the current fiscal year.

Insider Activity at Catalent

In other Catalent news, insider Ricky Hopson sold 662 shares of the stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the completion of the transaction, the insider now owns 29,974 shares in the company, valued at $1,785,251.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the transaction, the chief executive officer now owns 177,521 shares in the company, valued at approximately $10,431,133.96. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Ricky Hopson sold 662 shares of Catalent stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.56, for a total value of $39,428.72. Following the completion of the transaction, the insider now owns 29,974 shares of the company’s stock, valued at approximately $1,785,251.44. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,409 shares of company stock valued at $782,923. 0.31% of the stock is owned by corporate insiders.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.